About: covid:PMC7366117

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:PMC7366117 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
Creator	Bove, Sergio Albini, Elena Beindorf, Eva Capra, Ruggero Cordioli, Cinzia Cossi, Stefania De Rossi, Nicola Filippini, Chiara Flamminio, Gigliola Giansiracusa, Paola Manfredini, Silvano Mosca, Carlo Rasia, Sarah Rizzoni, Damiano Romanelli, Giuseppe Scarpazza, Cristina Scipione, Vittorio Vettoretto, Nereo Mancinelli, Chiara
is schema:about of	named entity 'dose' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'COVID' named entity 'inflammatory cytokines' named entity 'tocilizumab' named entity 'survival rates' named entity 'older age' named entity 'COVID' named entity 'heart disease' named entity 'mmc' named entity 'pharmacodynamic' named entity 'COVID' named entity 'respiratory distress' named entity 'diabetes' named entity 'cardiopathy' named entity 'retrospective cohort study' named entity 'pulmonary embolism' named entity 'clinical characteristics' named entity 'Th17' named entity 'respiratory support' named entity 'lymphocytes' named entity 'invasive ventilation' named entity 'COVID-19' named entity 'mortality rate' named entity 'tocilizumab' named entity 'risk of death' named entity 'tocilizumab' named entity 'lungs' named entity 'non-invasive' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'clinical trials' named entity 'normal range' named entity 'Italian' named entity 'COVID' named entity 'standard treatment' named entity 'IL-6' named entity 'COVID' named entity 'CRP' named entity 'MERS' named entity 'COVID' named entity 'rheumatological' named entity 'meta-analysis' named entity 'Statistical significance' named entity 'inflammation' named entity 'RT-PCR' named entity 'IL-6 receptor' named entity 'pro-inflammatory' named entity 'subacute' named entity 'thromboembolic' named entity 'posology' named entity 'bacterial infections' named entity 'survival rate' named entity 'COVID-19' named entity 'diabetes' named entity 'CCL2' named entity 'proportional hazard model' named entity 'comorbidities' named entity 'respiratory failure' named entity 'reverse-transcriptase' named entity 'transaminase' named entity 'tocilizumab' named entity 'heart disease' named entity 'tocilizumab' named entity 'FiO2' named entity 'tocilizumab' named entity 'COVID-19' named entity 'body temperature' named entity 'Hazard Ratio' named entity 'CD8' named entity 'tocilizumab' named entity 'COVID' named entity 'invasive ventilation' named entity 'hypertension' named entity 'PaO2/FiO2' named entity 'respiratory support' named entity 'COVID-19' named entity 'mortality rate' named entity 'tocilizumab'

Attributes

Values

Creator

Bove, Sergio
Albini, Elena
Beindorf, Eva
Capra, Ruggero
Cordioli, Cinzia
Cossi, Stefania
De Rossi, Nicola
Filippini, Chiara
Flamminio, Gigliola
Giansiracusa, Paola
Manfredini, Silvano
Mosca, Carlo
Rasia, Sarah
Rizzoni, Damiano
Romanelli, Giuseppe
Scarpazza, Cristina
Scipione, Vittorio
Vettoretto, Nereo
Mancinelli, Chiara

is schema:about of

named entity 'dose'
named entity 'tocilizumab'
named entity 'tocilizumab'
named entity 'COVID'
named entity 'inflammatory cytokines'
named entity 'tocilizumab'
named entity 'survival rates'
named entity 'older age'
named entity 'COVID'
named entity 'heart disease'
named entity 'mmc'
named entity 'pharmacodynamic'
named entity 'COVID'
named entity 'respiratory distress'
named entity 'diabetes'
named entity 'cardiopathy'
named entity 'retrospective cohort study'
named entity 'pulmonary embolism'
named entity 'clinical characteristics'
named entity 'Th17'
named entity 'respiratory support'
named entity 'lymphocytes'
named entity 'invasive ventilation'
named entity 'COVID-19'
named entity 'mortality rate'
named entity 'tocilizumab'
named entity 'risk of death'
named entity 'tocilizumab'
named entity 'lungs'
named entity 'non-invasive'
named entity 'tocilizumab'
named entity 'tocilizumab'
named entity 'tocilizumab'
named entity 'clinical trials'
named entity 'normal range'
named entity 'Italian'
named entity 'COVID'
named entity 'standard treatment'
named entity 'IL-6'
named entity 'COVID'
named entity 'CRP'
named entity 'MERS'
named entity 'COVID'
named entity 'rheumatological'
named entity 'meta-analysis'
named entity 'Statistical significance'
named entity 'inflammation'
named entity 'RT-PCR'
named entity 'IL-6 receptor'
named entity 'pro-inflammatory'
named entity 'subacute'
named entity 'thromboembolic'
named entity 'posology'
named entity 'bacterial infections'
named entity 'survival rate'
named entity 'COVID-19'
named entity 'diabetes'
named entity 'CCL2'
named entity 'proportional hazard model'
named entity 'comorbidities'
named entity 'respiratory failure'
named entity 'reverse-transcriptase'
named entity 'transaminase'
named entity 'tocilizumab'
named entity 'heart disease'
named entity 'tocilizumab'
named entity 'FiO2'
named entity 'tocilizumab'
named entity 'COVID-19'
named entity 'body temperature'
named entity 'Hazard Ratio'
named entity 'CD8'
named entity 'tocilizumab'
named entity 'COVID'
named entity 'invasive ventilation'
named entity 'hypertension'
named entity 'PaO2/FiO2'
named entity 'respiratory support'
named entity 'COVID-19'
named entity 'mortality rate'
named entity 'tocilizumab'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software